Potential beneficial effect of treatment with PCSK9 inhibitors on vascular endothelial dysfunction: a systematic review and meta-analysis
- 4 May 2026
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 19 (5) , 491-498
Abstract
1. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors – evolocumab and alirocumab– have been approved by the US Food and Drug Administration and the European Union for the treatment o...Keywords
This publication has 41 references indexed in Scilit:
- PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular diseaseClinical Research in Cardiology, 2024
- Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal AntibodiesAmerican Journal of Preventive Cardiology, 2024
- Effect of Evolocumab in Patients with Chronic Limb-Threatening IschemiaCardiovascular Revascularization Medicine, 2024
- Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudyAtherosclerosis, 2024
- Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaqueAtherosclerosis, 2023
- The addition of evolocumab to maximal tolerated statin therapy improves walking performance in patients with peripheral arterial disease and intermittent claudication (Evol-PAD study)Cardiovascular Revascularization Medicine, 2023
- Smoking and diabetes attenuate beneficial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levelsAtherosclerosis Plus, 2022
- The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular DiseaseCardiovascular Drugs and Therapy, 2021
- Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical TranslationCurrent Atherosclerosis Reports, 2018
- Oxidatively modified human low-density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivoZeitschrift für Die Gesamte Experimentelle Medizin, 1991